Full-Time
DevOps / Systems Engineer
Collate
11-50 employees
AI-driven documentation automation for life sciences
Compensation Overview
$150k - $300k/yr
San Francisco, CA, USA
In Person
 DevOps & Infrastructure (1) |
|---|
- Hands-on experience with cloud infrastructure (AWS, GCP, or similar) and modern DevOps practices.
- Proficiency with infrastructure-as-code and CI/CD tooling.
- Familiarity with monitoring, observability, and incident management.
- Interest or experience in light security work, including certificates, secrets management, or compliance support.
- A pragmatic approach: able to balance iteration speed with building for long-term reliability.
- Motivation to work in an early-stage startup where your infrastructure decisions shape the foundation of the company.
- Design and maintain cloud infrastructure to support Collate’s products as we grow from prototypes to production scale.
- Develop CI/CD pipelines and automation that accelerate developer velocity and reduce operational friction.
- Manage core system reliability, including monitoring, logging, and incident response.
- Take on light security responsibilities, such as handling certificates, secrets management, and supporting compliance needs.
- Collaborate closely with engineering teams to design infrastructure that balances speed, safety, and scale.
- Continuously improve internal tooling and workflows, helping the team move faster with confidence.
- Leverage tooling including AWS, Terraform, Kubernetes, Helm, ArgoCD, Grafana, and Github Actions.
Collate provides an AI-powered platform that automates the creation and management of documentation for drug development, medical devices, and diagnostics. It works by generating, organizing, and governing regulatory and quality documents while offering data discovery and governance tools to ensure high-quality data assets. It distinguishes itself by offering an end-to-end, life-sciences–focused solution that covers drug, device, and diagnostic workflows in one platform, reducing manual work and speeding up approvals. Its goal is to shorten development and regulatory timelines so researchers can focus on discovery and bring life-saving innovations to patients faster.
Company Size
11-50
Company Stage
Seed
Total Funding
$30M
Headquarters
San Francisco, California
Founded
2025
Simplify's Take
What believers are saying
- Pfizer's 20% manufacturing throughput gains validate AI documentation automation market demand.[5]
- UCSF ARPA-H funding accelerates open-source drug development, creating IND filing opportunities.[5]
- Moderna's AWS AI integration demonstrates enterprise adoption of automated quality control workflows.[5]
What critics are saying
- Pfizer's proprietary generative AI platform directly competes in manufacturing documentation automation.[5]
- FDA's DARRTS system with AI language models bypasses Collate's regulatory submission tools.[7]
- Open-source models from UCSF and Open Molecular Software Foundation commoditize documentation automation.[5]
What makes Collate unique
- Acquired MantleBio to deepen AI capabilities across entire drug development lifecycle.[1]
- Generative AI automates regulatory submissions, clinical trials, and quality management workflows.[2][3]
- AI Studio and SDK enable custom agents without external infrastructure dependencies.[8]
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Equity
Flexible Work Hours
Professional Development Budget
Company News
Biotech startup Collate, founded by Surbhi Sarna, has secured a $30 million seed fund to automate paperwork in the life sciences industry using AI. The funding round was led by Redpoint, with participation from First Round, Conviction Partners, and YC, valuing Collate at over $100 million. Collate aims to streamline documentation for diagnostic, medical device, and drug development companies, enhancing R&D and reducing time to market. Co-founders Nate Smith and Jigish Patel bring additional expertise.
Y Combinator's Surbhi Sarna has raised $30 million for Collate, a startup aiming to automate the tedious parts of running a life sciences business using AI.